Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin combined with ADG106 for advanced hepatocellular carcinoma after prior PD-1/PD-L1 therapy
ChiCTR2000041353Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Icaritin and ADG106 in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Objective response rate and Disease remission rate. Started Jan 2021; status: recruiting.
02
Drugs
IcaritinADG106
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000041353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041353.